StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) stock

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)

Close on Nov 17, 2026Market cap $458.11MP/E –Yield –

Assembly Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Assembly Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$8.69M. For fiscal 2025 it was -$11.99M. The highest annual figure on record is -$11.99M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.99M–
FY2024Dec 31, 2024-$45.29M–
FY2023Dec 31, 2023-$64.20M–
FY2022Dec 31, 2022-$93.62M–
FY2021Dec 31, 2021-$132.22M–
FY2020Dec 31, 2020-$64.09M–
FY2019Dec 31, 2019-$102.22M–
FY2018Dec 31, 2018-$92.09M–
FY2017Dec 31, 2017-$52.01M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.32M–
Q1 FY2026Mar 31, 2026-$11.34M–
Q4 FY2025Dec 31, 2025$19.83M–
Q3 FY2025Sep 30, 2025-$10.85M–
Q2 FY2025Jun 30, 2025-$11.06M–
Q1 FY2025Mar 31, 2025-$9.91M–
Q4 FY2024Dec 31, 2024-$11.50M–
Q3 FY2024Sep 30, 2024-$10.92M–
Q2 FY2024Jun 30, 2024-$12.17M–
Q1 FY2024Mar 31, 2024-$10.70M–
Q4 FY2023Dec 31, 2023-$12.47M–
Q3 FY2023Sep 30, 2023-$14.93M–
Q2 FY2023Jun 30, 2023-$17.36M–
Q1 FY2023Mar 31, 2023-$19.44M–
Q4 FY2022Dec 31, 2022-$22.85M–
Q3 FY2022Sep 30, 2022-$23.27M–
Q2 FY2022Jun 30, 2022-$24.45M–
Q1 FY2022Mar 31, 2022-$23.04M–
Q4 FY2021Dec 31, 2021-$62.77M–
Q3 FY2021Sep 30, 2021-$18.76M–
Q2 FY2021Jun 30, 2021-$23.55M-451.4%
Q1 FY2021Mar 31, 2021-$27.15M–
Q4 FY2020Dec 31, 2020-$39.33M–
Q3 FY2020Sep 30, 2020-$3.88M–
Q2 FY2020Jun 30, 2020$6.70M–
Q1 FY2020Mar 31, 2020-$27.58M–
Q4 FY2019Dec 31, 2019-$28.57M–
Q3 FY2019Sep 30, 2019-$25.88M–
Q2 FY2019Jun 30, 2019-$19.58M–
Q1 FY2019Mar 31, 2019-$28.20M–
Q4 FY2018Dec 31, 2018-$26.15M–
Q3 FY2018Sep 30, 2018-$22.41M–
Q2 FY2018Jun 30, 2018-$27.02M–
Q1 FY2018Mar 31, 2018-$16.50M–

More Assembly Biosciences figures

See a number that looks wrong?